Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 01 May 2014
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Intarcia Therapeutics
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2012 Results from weeks 13-24 presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 03 Oct 2012 An analysis of data supporting dose selection for the global phase III programme of exenatide (12- and 24-week outcomes) was reported in an Intarcia Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History